Back to search

Article

Oral Baricitinib in the Treatment of Cutaneous Lichen Planus

2024-01-11

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Cutaneous lichen planus (LP) is a recalcitrant, difficult-to-treat, inflammatory skin disease characterized by pruritic, flat-topped, violaceous papules on the skin. Baricitinib is an oral Janus kinase (JAK) 1/2 inhibitor that interrupts the signaling pathway of interferon (IFN)-γ, a cytokine implicated in the pathogenesis of LP. <h4>Methods</h4> In this phase II trial, twe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1cc7bf06-74ab-546c-87c7-7471e716a8bd
DOI
10.1101/2024.01.09.24300946
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Oral Baricitinib in the Treatment of Cutaneous Lichen PlanusDOI 10.1101/2024.01.09.24300946
Select a neighboring publication to make it the new centre.